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Objective: We aimed at investigating the association of age-dependent IGF-I SDS with diabetes,
dyslipidemia, hypertension, and heart diseases, in a large patient sample.
Background: IGF-I has been suggested to be associated with several diseases and a prognostic marker for
the development of cardiovascular diseases and risk factors. The findings, though, have been
inconsistent possibly due to the methodological factors.
Methods: We studied 6773 consecutive primary care patients, aged 18C years, in a cross-sectional,
epidemiological study in primary care, Diabetes Cardiovascular Risk-Evaluation: Targets and Essential
Data for Commitment of Treatment study. All patients underwent a standardized clinical diagnostic
and laboratory assessment. IGF-I levels were measured with an automated chemiluminescence assay
system. We calculated the odds ratios (OR) for diseases in quintiles of IGF-I, and additionally analyzed
the association of age-dependent IGF-I SDS with these conditions.
Results: After multiple adjustments for confounders, we found increased ORs for coronary artery
disease in patients with high IGF-I. Women, but not men, with low IGF-I also showed increased ORs for
coronary artery disease. Dyslipidemia was positively associated with IGF-I. Type 2 diabetes showed a
curvilinear association with IGF-I SDS.
Conclusions: The findings suggest the existence of multiple and complex interactions between IGF-I and
several health conditions. The complex nature of disease- and subgroup-specific associations along
with the methodological factors can be held responsible for divergent findings in previous studies.
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Insulin-like growth factor-I (IGF-I) possesses proliferative
and anti-apoptotic properties, and is regulated by growth
hormone (GH). Apart from being a marker for patho-
logical GH over- and undersecretion (1–4), IGF-I variance
in the normal range has been suggested to be causally
related to the pathogenesis of several cardiovascular risk
factors and diseases such as insulin insensitivity and
diabetes (5, 6), coronary artery disease, and heart failure
(7–12). However, possibly due to the methodological
constraints (sampling, statistical analyses) of the available
clinical studies, the relationship of IGF-I with these
conditions and its pathogenic role remains partly
inconclusive and contradictory. Both protective (7, 10,
11) and detrimental (8, 9, 12) effects of IGF-I onn Journal of Endocrinologycardiovascular risk have been reported. Low IGF-I has
been associated with the presence (7) and risk of
developing coronary artery disease (10) and with
cardiovascular mortality (11). In other studies, differing
results were obtained. Thus, IGF-I has been found to be
positively associated with progression of coronary artery
stenosis and restenosis (8, 9) and coronary artery disease
(12). Heart failure has been found to be associated with
low IGF-I (13–16). In some studies on patients with heart
failure, positive effects of GH or IGF-I on cardiac function
have been found (17, 18), whereas these effects could not
be reproduced in other studies (19, 20). A recent
meta-analysis on 12 studies evaluating GH therapy in
195 patients with chronic heart failure has shown some
beneficial effects on hemodynamics, but recommended
further research with larger trials (21). The literatureDOI: 10.1530/EJE-07-0600
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conditions has been extensively reviewed by Juul (22).
Patients with low IGF-I levels have been found to be at
increased risk of developing glucose intolerance (6). Results
from the Rotterdam Study suggest that a genetic
polymorphism leading to lower levels of serum IGF-I confers
a higher risk of diabetes and myocardial infarction (5).
States of pathological GH over and undersecretion,
which lead to pathological IGF-I levels, are associated with
specific systemic complications. In active acromegaly, and
thus a state of high IGF-I concentrations, cardiac
dysfunction with ventricular hypertrophy, hypertension,
and type 2 diabetes can be found along with other
complications (23). GH deficiency is associated with
atherosclerosis, diastolic dysfunction, decreased left
ventricular mass, type 2 diabetes, or dyslipidemia for
example (24).
Both GH secretion and IGF-I levels decrease with age
in adults. Recently, age-dependent reference values in
a large cohort of normal weight healthy subjects have
been published (25). These values were established
using an automated immunoassay system (Nichols
advantage) and showed a high grade of reproducibility
in different laboratories. This allows calculation of age-
dependent SDS of IGF-I and elimination of the effect of
age-related decline.
We have previously shown that age-dependent IGF-I
SDS show a curvilinear association with body mass
index (BMI) (26), in a large patient sample in primary
care. Based on this exploration, the present paper aims
to clarify the role of IGF-I by examining the association
of IGF-I with cardiovascular risk factors and diseases
using the same dataset.Subjects and methods
Subjects
The study was approved by the local ethics committee
and all patients gave written informed consent. IGF-I
was measured in 4013 women and 2760 men, a
random sample from the Diabetes Cardiovascular Risk-
Evaluation: Targets and Essential Data for Commitment
of Treatment study, which was the representative of the
total DETECT population.
DETECT is a large, multistage cross-sectional study of
55 518 unselected consecutive patients (59% women
and 41% men; over 17 years) from 3188 primary care
offices in Germany with a prospective 12-month
component in a random subset of 7519 patients and
851 primary care settings. The initial physician
response rate was 60.2%, and further adjustments for
non-response, regional distribution, and attrition were
performed. For all patients, a comprehensive standar-
dized clinical evaluation (patients self-report and
physicians’ assessments) was conducted. Patients were
additionally characterized by an extensive standardizedwww.eje-online.orglaboratory program focusing on cardiovascular (CV)
risk assessment. For technical reasons, IGF-I measure-
ments were available only in 6773 patients. These
patients constituted the sample studied here. Table 1
summarizes patient characteristics in detail. Further
details are available at http://www.detect-studie.de.
Design, methods, and patient baseline characteristics,
as well as prevalences of health conditions and diseases
have been published (27).Instruments and measures
The main target of the DETECT study was the
assessment of cardiovascular risk. Therefore, physicians
were asked to diagnose diabetes mellitus, dyslipidemia,
hypertension, and coronary artery disease (CAD) as
definite, possible, or not present. CAD was defined as the
history of myocardial infarction, coronary intervention,
bypass surgery, or angiographically documented coron-
ary atherosclerosis. Patients with unclear findings were
excluded from the analysis for CAD (NZ160). In the
case of diabetes, type 1 or type 2 was indicated. Other
diagnoses were assessed by checkboxes without further
specifications. Current cardiovascular medication was
recorded. Laboratory values, obtained from the central
laboratory in Graz were additionally used for the
diagnosis of dyslipidemia and diabetes. Doctors were
instructed to measure the weight, height, and blood
pressure according to a standardized protocol. Systolic
and diastolic blood pressure was measured by indirect
cuff sphygmomanometry after several minutes of rest in
the sitting position.
For the assessment of diseases and risk factors,
physician’s diagnoses (definite diagnoses) in addition to
the parameters described below were used. Patients with
a possible physician’s diagnosis, but no further labora-
tory or clinical finding confirming this diagnosis, were
excluded from the evaluation of the respective diagnosis.
For the following diagnoses, these additional criteria
established or confirmed the diagnosis: dyslipidemia –
levels above total cholesterol O240 mg/dl, low density
lipoprotein (LDL) cholesterol O160 mg/dl or high
density lipoprotein (HDL) cholesterol !40 mg/dl, or
intake of lipid-lowering medication; hypertension –
systolic blood pressure (SBP) R140 mmHg or diastolic
blood pressure (DBP) R90 mmHg, or intake of anti-
hypertensive medication (NHANES criteria); type 2
diabetes – fasting blood glucose level R126 mg/dl or
intake of oral antidiabetic drugs.IGF-I measurements
Blood samples were collected and shipped by courier at
room temperature within 24 h to the central laboratory at
the Medical University of Graz (Austria). Upon arrival, the
samples were centrifuged immediately and serum was
stored at K20 8C until further processing. IGF-I was
determined with an automated chemiluminiscence system
Table 1 Patients characteristics in the study sample.
Total (NZ6773)a Female (NZ4013) Male (NZ2760)
N % N % N %
Total
Age group, 18–44 years 1429 21.1 958 23.9 471 17.1
Age group, 45–65 years 3050 45.0 1718 42.8 1332 48.3
Age group, 66C years 2294 33.9 1337 33.3 957 34.7
Smoker 1380 21.1 773 20.0 607 22.8
Ex-smoker 1574 24.1 551 14.2 1023 38.5
Non-smoker 3580 54.8 2551 65.8 1029 38.7
Ageb 57.7 (14.3) 57.0 (14.9) 58.8 (13.4)
BMIb 27.1 (4.9) 26.7 (5.2) 27.7 (4.3)
IGF-Ib 132.2 (54.4) 130.7 (55.5) 134.2 (52.6)
IGF-I SDSb 0.0 (0.9) 0.1 (0.9) K0.1 (0.9)
CAD 939 14.2 384 9.8 555 20.6
Myocardial infarction 343 5.1 96 2.4 247 9.0
Heart failure 675 10.0 365 9.1 310 11.2
Type 1 diabetes 52 0.8 30 0.8 22 0.8
Type 2 diabetes 1021 15.1 505 12.6 516 18.7
Hypertension 4104 60.6 2255 56.2 1849 67.0
Dyslipidemia 4267 63.9 2296 58.1 1971 72.3
Age group, 18–44 years
Ageb 37.2 (5.8) 37.1 (5.9) 37.6 (5.5)
BMIb 25.6 (5.2) 25.0 (5.5) 26.9 (4.5)
IGF-Ib 163.6 (56.7) 162.2 (56.4) 166.3 (57.3)
IGF-I SDSb K0.2 (0.8) K0.2 (0.8) K0.2 (0.9)
CAD 20 1.4 5 0.5 15 3.3
Myocardial infarction 6 0.4 0 0.0 6 1.3
Heart failure 8 0.6 3 0.3 5 1.1
Type 1 diabetes 13 0.9 8 0.8 5 1.1
Type 2 diabetes 38 2.7 23 2.4 15 3.2
Hypertension 371 26.0 195 20.4 176 37.4
Dyslipidemia 584 41.3 300 31.7 284 60.9
Age group, 45–65 years
Ageb 55.7 (6.4) 55.3 (6.4) 56.3 (6.3)
BMIb 27.4 (4.9) 27.0 (5.3) 28.1 (4.4)
IGF-Ib 130.4 (50.4) 129.1 (52.1) 132.1 (48.0)
IGF-I SDSb K0.1 (0.9) 0.0 (0.8) K0.1 (0.9)
CAD 298 10.0 96 5.7 202 15.5
Myocardial infarction 129 4.2 27 1.6 102 7.7
Heart failure 171 5.6 63 3.7 108 8.1
Type 1 diabetes 23 0.8 11 0.6 12 0.9
Type 2 diabetes 383 12.6 154 9.0 229 17.2
Hypertension 1787 58.6 928 54.0 859 64.5
Dyslipidemia 1969 65.3 987 58.2 982 74.3
Age group 66C
Ageb 73.1 (5.4) 73.5 (5.5) 72.6 (5.1)
BMIb 27.6 (4.3) 27.5 (4.6) 27.7 (3.8)
IGF-Ib 114.9 (49.4) 110.3 (48.5) 121.3 (49.9)
IGF-I SDSb 0.3 (0.9) 0.4 (0.9) 0.1 (0.9)
CAD 621 28.2 283 22.1 338 36.5
Myocardial infarction 208 9.1 69 5.2 139 14.5
Heart failure 496 21.6 299 22.4 197 20.6
Type 1 diabetes 16 0.7 11 0.8 5 0.5
Type 2 diabetes 600 26.2 328 24.5 272 28.4
Hypertension 1946 84.8 1132 84.7 814 85.1
Dyslipidemia 1714 76.1 1009 76.9 705 74.9
aNZ6773 valid IGF-I measurements.
bData are expressed as mean (S.D.).
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The maximal intra- and inter-assay coefficients of variation
were 5 and 7% respectively. Reagents and secondary
standard were used as recommended by the manufacturer.
IGF-I levels were transformed to age-dependent IGF-I SDS,
according to Brabant et al. (25).Statistical analyses
We sought to determine the associations of IGF-I and IGF-I
SDS with different potential confounders by calculating
correlations and partial correlations or b coefficients for
different conditions. We divided the study sample scoreswww.eje-online.org
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adjusted for sex, BMI, age, aspartate aminotransferase
(AST), glomerular filtration rate (GFR) and smoking were
calculated for each clinical condition considered in this
paper, using the 1st quintile representing the lowest and
the 5th quintile representing the highest IGF-I levels.
Adjustment for AST as a marker of liver disease was done
because IGF-I levels are decreased in liver diseases. Also,
AST correlated weakly with both IGF-I and IGF-I SDS in
our population. Adjustment for GFR was done because we
found a weak negative correlation of IGF-I SDS with GFR.
To evaluate both linear and curvilinear effects, we
performed analyses using both the 1st and 3rd quintile
as references. We additionally analyzed the OR for CAD,
myocardial infarction, and heart failure after additional
adjustment for hypertension, diabetes, and dyslipidemia.
All analyses were also performed in the subgroups of sex
and age groups of 18–44, 45–65, and 66 years or older.Table 2 Odds ratio (OR) for health conditions in insulin-like growth fa
1st quintile
(!90)
2nd quintile (90–113) 3rd q
(Ref) OR 95% CI O
Adjusted for age, gender, BMI, AST, GFR and smoking status
Total
CAD 1.0 0.8–1.3 0
Myocardial infarction 0.9 0.7–1.4 1
Heart failure 0.9 0.7–1.1 0
Type 1 diabetes 1.3 0.6–2.9 0
Type 2 diabetes 0.9 0.7–1.1 0
Hypertension 0.9 0.8–1.1 1
Dyslipidemia 1.1 0.9–1.3 1
Female
CAD 1.0 0.7–1.3 0
Myocardial infarction 0.9 0.5–1.8 1
Heart failure 1.1 0.8–1.5 0
Type 1 diabetes 1.4 0.6–3.7 0
Type 2 diabetes 1.0 0.7–1.3 0
Hypertension 0.9 0.7–1.2 0
Dyslipidemia 1.1 0.9–1.4 1
Male
CAD 1.1 0.8–1.6 0
Myocardial infarction 0.9 0.6–1.5 1
Heart failure 0.7 0.5–1.0 0
Type 1 diabetes 1.3 0.3–5.5 0
Type 2 diabetes 0.8 0.6–1.1 0
Hypertension 1.0 0.7–1.4 1
Dyslipidemia 1.0 0.7–1.3 1
Adjusted for age, gender, AST, GFR, BMI, diabetes, hypertension, dy
Total
CAD 1.0 0.8–1.3 0
Myocardial infarction 1.0 0.7–1.4 1
Heart failure 0.9 0.7–1.2 0
Female
CAD 1.0 0.7–1.3 0
Myocardial infarction 1.0 0.5–1.9 1
Heart failure 1.1 0.8–1.5 0
Male
CAD 1.1 0.8–1.6 0
Myocardial infarction 0.9 0.6–1.5 1
Heart failure 0.7 0.5–1.1 0
Bold highlighted OR are significant at the 5% level.
www.eje-online.orgTo evaluate the effects of abnormally high or low
values, we also calculated the IGF-I SDS distribution and
determined the OR in different S.D. ranges of IGF-I SDS.
Even though the effect of age-related decline on IGF-I
levels is excluded using IGF-I SDS, we have also adjusted
for age because it was shown previously that there is an
albeit weak, positive correlation between IGF-I SDS and
age (26). All statistical analyses were conducted with
the software package STATA 8 (Stata Corp, College
Station, TX, USA).Results
The prevalence of the cardiovascular conditions studied
were comparable in the laboratory sample (NZ7519)
and the sample studied here (NZ6773, maximal
difference in prevalence: 0.3%).ctor-I (IGF-I) quintiles, using the 1st quintile as the reference.
uintile (114–137) 4th quintile (138–170) 5th quintile (O170)
R 95% CI OR 95% CI OR 95% CI
.8 0.6–1.0 1.1 0.8–1.4 1.2 0.9–1.6
.1 0.7–1.5 1.3 0.9–1.9 1.1 0.7–1.6
.8 0.6–1.0 0.9 0.7–1.2 1.0 0.7–1.3
.6 0.3–1.6 0.4 0.2–1.1 0.3 0.1–0.9
.9 0.7–1.1 0.9 0.7–1.1 0.9 0.7–1.1
.0 0.8–1.2 1.0 0.8–1.2 1.1 0.9–1.4
.1 0.9–1.3 1.2 1.0–1.4 1.3 1.1–1.5
.7 0.5–1.0 1.0 0.7–1.5 1.3 0.8–1.9
.1 0.6–2.2 1.3 0.7–2.5 1.5 0.7–3.1
.8 0.6–1.2 0.9 0.6–1.3 0.9 0.5–1.4
.6 0.2–1.9 0.3 0.1–1.1 0.3 0.1–1.6
.9 0.7–1.3 1.0 0.7–1.4 1.1 0.7–1.6
.9 0.7–1.2 0.8 0.7–1.1 1.0 0.8–1.4
.1 0.9–1.4 1.2 1.0–1.5 1.5 1.2–1.9
.9 0.7–1.3 1.1 0.8–1.6 1.2 0.8–1.7
.0 0.6–1.6 1.3 0.8–2.0 1.0 0.6–1.6
.8 0.5–1.2 0.8 0.6–1.3 1.1 0.7–1.6
.7 0.1–3.4 0.6 0.1–2.6 0.2 0.0–1.4
.8 0.6–1.2 0.7 0.5–1.0 0.7 0.5–1.0
.1 0.8–1.5 1.2 0.9–1.6 1.3 0.9–1.8
.2 0.9–1.6 1.2 0.9–1.6 1.0 0.8–1.4
slipidemia and smoking status
.8 0.6–1.0 1.0 0.8–1.3 1.2 0.9–1.6
.1 0.7–1.6 1.2 0.8–1.8 1.1 0.7–1.6
.8 0.6–1.1 0.8 0.6–1.1 1.0 0.7–1.3
.7 0.5–1.0 1.0 0.7–1.4 1.2 0.8–1.8
.2 0.6–2.4 1.2 0.6–2.4 1.5 0.7–3.1
.7 0.5–1.1 0.8 0.5–1.2 0.8 0.5–1.2
.9 0.7–1.3 1.1 0.8–1.5 1.2 0.8–1.7
.0 0.6–1.6 1.2 0.7–1.9 0.9 0.5–1.5
.9 0.6–1.3 0.9 0.6–1.3 1.1 0.7–1.8
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positive correlation with age. After controlling for
age, sex, and BMI (if applicable), there were weak
negative correlations of both IGF-I and IGF-I SDS
with BMI, GFR, HDL cholesterol, triglycerides, AST,
and g-glutamyl transferase, and weak positive
correlations with creatinine and lipoprotein (a).
There were no significant correlations with HbA1c,
blood glucose, or blood pressure. We found diverging
associations of smoking status, cancer, or postme-
nopausal hormone replacement therapy with IGF-I
and IGF-I SDS. However, after controlling for age,
sex, and BMI, the associations with cancer or
hormone replacement therapy were no longer
significant, and smoking was negatively associated
with both IGF-I (PZ0.06) and IGF-I SDS (P!0.01;
data not shown).Table 3 Odds ratio (OR) for health conditions in insulin-like growth fa
1st quintile
(!90)
2nd quintile
(90–113)
OR 95% CI OR 95% C
Adjusted for age, gender, AST, GFR, BMI, diabetes, hypertension, dy
Total
CAD 1.2 1.0–1.6 1.3 1.0–1.6
Myocardial infarction 1.0 0.7–1.4 0.9 0.6–1.3
Heart failure 1.3 1.0–1.7 1.1 0.9–1.5
Type 1 diabetes 1.6 0.6–3.9 2.1 0.9–4.8
Type 2 diabetes 1.1 0.9–1.4 1.0 0.8–1.3
Hypertension 1.0 0.8–1.2 0.9 0.8–1.1
Dyslipidemia 0.9 0.8–1.1 1.0 0.8–1.1
Female
CAD 1.5 1.0–2.1 1.4 1.0–2.1
Myocardial infarction 0.9 0.5–1.7 0.8 0.4–1.6
Heart failure 1.3 0.9–1.8 1.3 0.9–2.0
Type 1 diabetes 1.6 0.5–4.7 2.2 0.8–6.4
Type 2 diabetes 1.1 0.8–1.5 1.1 0.8–1.5
Hypertension 1.1 0.8–1.4 1.0 0.7–1.2
Dyslipidemia 0.9 0.7–1.2 1.0 0.8–1.3
Male
CAD 1.1 0.8–1.5 1.2 0.9–1.7
Myocardial infarction 1.0 0.6–1.5 0.9 0.6–1.5
Heart failure 1.3 0.9–1.9 0.9 0.6–1.3
Type 1 diabetes 1.5 0.3–7.6 2.0 0.5–7.5
Type 2 diabetes 1.2 0.9–1.6 0.9 0.7–1.3
Hypertension 0.9 0.7–1.2 0.9 0.7–1.2
Dyslipidemia 0.9 0.6–1.2 0.9 0.6–1.1
Adjusted for age, gender, BMI, AST, GFR and smoking status
Total
CAD 1.2 1.0–1.6 1.3 1.0–1.6
Myocardial infarction 0.9 0.6–1.3 0.9 0.6–1.3
Heart failure 1.3 1.0–1.6 1.1 0.9–1.5
Female
CAD 1.5 1.0–2.2 1.5 1.0–2.2
Myocardial infarction 0.8 0.4–1.6 0.8 0.4–1.7
Heart failure 1.3 0.9–2.0 1.4 1.0–2.1
Male
CAD 1.1 0.7–1.5 1.2 0.9–1.7
Myocardial infarction 1.0 0.6–1.6 0.9 0.6–1.5
Heart failure 1.1 0.8–1.7 0.8 0.6–1.3
Bold highlighted OR are significant at the 5% level.Table 2 reports the IGF-I quintiles and their
associations with clinical conditions using the 1st
quintile as the reference. The OR for type 1 diabetes
was decreased in the 5th quintile. The OR for
dyslipidemia was increased in the 4th and 5th quintiles.
Some findings remained significant only in women but
not in men. We additionally examined these associ-
ations using the 3rd quintile as reference (Table 3).
Here, the 4th and 5th quintiles were associated with
CAD. These findings remained significant only in
women. Additionally, in women, there were increased
OR for CAD in the lowest quintile and for dyslipidemia in
the highest quintile. The association with CAD
remained significant after additional adjustment for
hypertension, dyslipidemia, and diabetes.
Figure 1 shows the OR for CAD, after adjustment for
sex, age, BMI, AST, GFR, and smoking in the total agector-I (IGF-I) quintiles, using the 3rd quintile as the reference.
3rd quintile
(114–137)
4th quintile
(138–170)
5th quintile
(O170)
I (Ref) OR 95% CI OR 95% CI
slipidemia and smoking status
1.3 1.0–1.7 1.5 1.1–1.9
1.2 0.9–1.8 1.0 0.7–1.6
1.1 0.8–1.5 1.2 0.9–1.7
0.7 0.3–1.8 0.4 0.1–1.3
1.0 0.8–1.2 1.0 0.8–1.3
1.0 0.8–1.2 1.1 0.9–1.4
1.1 0.9–1.3 1.2 1.0–1.4
1.5 1.0–2.3 1.8 1.2–2.9
1.1 0.6–2.3 1.3 0.6–2.8
1.1 0.7–1.7 1.1 0.7–1.8
0.4 0.1–2.0 0.5 0.1–2.5
1.1 0.7–1.5 1.2 0.8–1.7
0.9 0.7–1.1 1.1 0.9–1.4
1.1 0.9–1.4 1.4 1.1–1.7
1.2 0.9–1.7 1.3 0.9–1.8
1.2 0.8–1.9 0.9 0.6–1.5
1.1 0.7–1.6 1.3 0.9–2.1
0.9 0.3–3.2 0.2 0.0–1.5
0.9 0.6–1.2 0.9 0.6–1.2
1.1 0.8–1.4 1.2 0.9–1.5
1.1 0.8–1.4 0.9 0.7–1.2
1.3 1.0–1.6 1.5 1.1–1.9
1.1 0.8–1.7 1.0 0.7–1.5
1.1 0.8–1.4 1.2 0.9–1.7
1.4 0.9–2.2 1.8 1.1–2.9
1.0 0.5–2.1 1.2 0.6–2.6
1.1 0.7–1.7 1.0 0.6–1.7
1.1 0.8–1.6 1.2 0.9–1.8
1.2 0.8–1.8 0.9 0.6–1.5
1.0 0.7–1.5 1.3 0.8–2.0
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Figure 1 IGF-I and coronary artery disease.
Odds ratios and confidence intervals for the
prevalence of coronary artery disease
according to IGF-I quintiles in the total group
and different age groups, adjusted for sex,
age, BMI, AST, GFR, and smoking.
Reference: 3rd quintile.
Table 4 Odds ratios (OR) for health conditions in insulin-like growth factor-I (IGF-I) SDS groups, using K1 to 1 S.D. as reference.
!K2 IGF-I SDS
(NZ82)
K2%IGF-I SDS
!K1 (NZ667)
K1%IGF-I SDS
%1 (NZ5118)
1! IGF-I SDS
%2 (NZ781)
IGF-I SDS
O2 (NZ125)
OR 95% CI OR 95% CI (Ref) OR 95% CI OR 95% CI
Adjusted for age, gender, BMI, AST, GFR and smoking status
Total
CAD 0.3 0.1–1.0 1.2 0.9–1.6 1.3 1.1–1.7 1.0 0.6–1.7
Myocardial infarction 0.3 0.0–2.1 1.2 0.8–1.9 1.3 0.9–1.8 1.1 0.5–2.3
Heart failure 1.2 0.4–3.3 1.6 1.1–2.2 1.4 1.1–1.7 1.1 0.6–1.9
Type 1 diabetes 3.4 0.7–16.5 1.2 0.5–2.8 0.4 0.1–1.5 1.2 0.2–8.8
Type 2 diabetes 2.3 1.1–4.6 1.5 1.1–1.9 1.1 0.9–1.4 2.2 1.3–3.6
Hypertension 1.1 0.6–2.1 1.1 0.9–1.3 1.3 1.1–1.6 1.0 0.6–1.6
Dyslipidemia 0.8 0.5–1.4 1.0 0.8–1.2 1.4 1.2–1.7 1.6 1.0–2.5
Female
CAD 1.6 0.9–2.6 1.3 1.0–1.8 0.9 0.5–1.8
Myocardial infarction 2.1 0.9–5.0 1.8 1.1–3.0 0.7 0.2–3.2
Heart failure 1.4 0.1–13.5 1.6 0.9–2.7 1.2 0.9–1.7 0.8 0.4–1.6
Type 1 diabetes 4.7 0.5–42.1 1.6 0.5–4.8 0.3 0.0–2.1 1.8 0.2–13.7
Type 2 diabetes 4.4 1.1–17.7 1.7 1.2–2.5 1.1 0.8–1.5 2.4 1.3–4.4
Hypertension 0.8 0.3–2.4 1.4 1.1–1.9 1.3 1.0–1.7 0.8 0.5–1.5
Dyslipidemia 1.2 0.6–2.7 1.0 0.8–1.4 1.4 1.1–1.8 1.6 0.9–2.9
Male
CAD 0.4 0.1–1.2 1.1 0.8–1.5 1.3 1.0–1.8 1.1 0.5–2.5
Myocardial infarction 0.3 0.0–2.5 1.1 0.7–1.7 1.0 0.7–1.6 1.4 0.6–3.3
Heart failure 1.1 0.3–3.2 1.6 1.1–2.3 1.5 1.0–2.2 1.8 0.7–4.1
Type 1 diabetes 3.9 0.5–33.7 0.9 0.2–4.0 0.4 0.0–3.9
Type 2 diabetes 1.8 0.8–4.0 1.3 1.0–1.8 1.0 0.7–1.5 1.8 0.7–4.6
Hypertension 1.3 0.6–3.0 0.9 0.6–1.1 1.2 0.9–1.7 1.1 0.5–2.6
Dyslipidemia 0.8 0.4–1.6 1.1 0.8–1.4 1.3 0.9–1.7 1.2 0.6–2.7
Adjusted for age, gender, AST, GFR, BMI, diabetes, hypertension, dyslipidemia and smoking status
Total
CAD 0.3 0.1–0.9 1.2 0.9–1.6 1.2 1.0–1.5 0.9 0.6–1.6
Myocardial infarction 0.3 0.0–2.0 1.3 0.8–1.9 1.2 0.9–1.7 1.0 0.5–2.1
Heart failure 1.1 0.4–3.1 1.5 1.1–2.1 1.3 1.0–1.6 1.0 0.6–1.8
Female
CAD 1.3 0.8–2.3 1.2 0.9–1.6 0.8 0.4–1.6
Myocardial infarction 2.0 0.9–4.8 1.7 1.0–2.8 0.6 0.1–2.7
Heart failure 1.1 0.1–11.2 1.5 0.8–2.6 1.1 0.8–1.5 0.7 0.3–1.5
Male
CAD 0.4 0.1–1.1 1.2 0.8–1.7 1.3 0.9–1.8 1.1 0.5–2.4
Myocardial infarction 0.3 0.0–2.5 1.1 0.7–1.8 1.0 0.6–1.5 1.3 0.5–3.2
Heart failure 1.0 0.4–3.1 1.6 1.0–2.3 1.5 1.0–2.2 1.7 0.7–4.0
Bold highlighted OR are significant at the 5% level.
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Figure 2 IGF-I SDS and type 2 diabetes.
Odds ratios and confidence intervals for
the prevalence of type 2 diabetes
according to IGF-I SDS groups in the total
group and different age groups, adjusted
for sex, age, BMI, AST, GFR, and smoking.
Reference: IGF-I SDS,K1 to 1S.D.
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significant findings in the 4th and 5th quintile. The
findings in the 5th quintile remained significant in
patients aged 66 years or more.
We further analyzed the ORs for different ranges of
IGF-I SDS to examine the effect of elevated and
decreased levels of IGF-I SDS in the normal and
pathological range, as shown in Table 4. When
compared with the IGF-I SDS range of K1 to 1, the
OR for type 2 diabetes was increased both in patients
with low (less than K2 SDS and K2 to K1 SDS) and
abnormally elevated IGF-I SDS (O2 SDS). As shown in
Fig. 2, this effect was more pronounced in patients aged
18–44 years but not significant in older subjects.
We found an increased OR for CAD, dyslipidemia, and
hypertension in the high to normal IGF-I SDS ranges.
Heart failure was more common both in patients with
K2 to K1 SDS and 1 to 2 SDS. Sex-specific analyses
revealed that the effects on type 2 diabetes (at IGF-I SDS
O2), dyslipidemia, and hypertension were also present
in women but not in men, whereas the effects on heart
failure were only present in men but not in women.Discussion
To our knowledge, this is the largest study assessing the
association of IGF-I with the prevalence of different
cardiovascular diseases and risk factors, allowing
re-examination of the controversial issue of IGF-I-
associated health conditions. Age-dependent IGF-I SDS
calculated from the largest published reference sample
for IGF-I measurement (25) were used in addition to the
IGF-I levels to analyze associations between IGF-I and
various health conditions. Moreover, as we have
previously shown, there is a significant curvilinearassociation of BMI with IGF-I SDS (26). So far, few
studies on IGF-I and diseases have adjusted for BMI. This
could possibly have confounded their results. Therefore,
we have adjusted for BMI in our analyses in addition to
other adjustments.
The key findings of our study are: a) no clear-cut linear
increase or decline of any parameter with IGF-I, b) increased
prevalences of CAD and dyslipidemia with high IGF-I, c)
increased prevalence of CAD in women with low IGF-I, and
d) curvilinear associations of IGF-I SDS with type 2 diabetes.
The presence of dyslipidemia was found to be increasing
with higher IGF-I. This was also significant only in
women. In acromegaly, dyslipidemia has also been found
to be more common. Possibly, similar effects as in
acromegaly play a role in this association. The prevalence
of CAD was increased in patients with high IGF-I levels.
This association was still present after adjustment for
hypertension, dyslipidemia, and diabetes, indicating that
this association is independent of the cardiovascular risk
factors. This supports the findings of some authors who
showed IGF-I to be associated with increased risk of CAD,
possibly due to proliferative effects of IGF-I on the vascular
intima and atherosclerosis (8). Interestingly, in women
with low IGF-I, there were also increased OR for CAD. This
curvilinear association in women might explain the
diverging findings in the literature, which were mainly
obtained from smaller samples. Our results, thus, also
support the findings assuming a protective effect of IGF-I
on CAD, though only in women (9–11).
Heart failure was more common in subjects with low
IGF-I levels. Low IGF-I has been associated with heart
failure and therapeutic approaches of GH or IGF-I in this
field have been performed, but no clear benefit could be
demonstrated in placebo-controlled trials (17–20).
The decrease of type 2 diabetes with increasing IGF-I
SDS is in line with the previous observations that low IGF-I
levels predispose to diabetes. It has been shown thatwww.eje-online.org
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levels have increased prevalences of diabetes (5) and low
IGF-I levels increase the future risk of glucose intolerance
(6). Therefore, we can speculate that the increased
prevalence of type 2 diabetes in our subjects with low
IGF-I SDS is a consequence rather than a cause of IGF-I
levels. However, the association was not linear, and in
subjects with abnormally high IGF-I SDS the prevalence of
type 2 diabetes was also increased. Type 2 diabetes is also
more common in acromegaly that has been assumed to be
due to the insulin antagonistic effects of GH (23). We have
not assessed GH secretion in our study. Therefore, it is not
clear whether higher GH secretion is the cause of high
IGF-I levels and, possibly, increased risk of diabetes.
Taken together, our results show multiple interactions
of IGF-I and several health conditions. Some limitations of
our study need to be addressed. Due to the cross-sectional
design of this study, we cannot prove whether the
associations are causally related or due to a common,
unknown third factor. Further prospective studies are
needed to assess the causal associations of IGF-I with
health conditions. With regard to cardiovascular risk
prevalences, the laboratory sample was comparable with
the total sample of the DETECT study (27), even though
the prevalence of dyslipidemia was slightly higher in the
laboratory sample. Even though a marginal selection bias
cannot be ruled out with certainty, we have no reason to
believe that this has a general effect on the associations of
IGF-I with these conditions. The IGF-I assay we used is no
longer available from the manufacturer, and we need to
address whether these results are valid for other assays as
well. Studies evaluating different IGF-I assays, including
the one used here, have found high intercorrelations with
all assays (28, 29); thus we think it is very likely that the
associations found are independent of the assay used.
The large-scale approach allows detailed subgroup
analyses. Our results demonstrate sex-specific associ-
ations of IGF-I with many health conditions and some
effects are restricted only to certain age groups. These
findings provide a possible explanation for the diverging
results reported in the literature, which were derived
from smaller samples.Acknowledgements
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